Filing Details
- Accession Number:
- 0001209191-20-065571
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-30 18:07:45
- Reporting Period:
- 2020-12-28
- Accepted Time:
- 2020-12-30 18:07:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
921299 | Fibrogen Inc | FGEN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1621333 | Kalevi Kurkijarvi | C/O Fibrogen, Inc. 409 Illinois St. San Francisco CA 94158 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-12-28 | 6,000 | $18.34 | 39,100 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-12-28 | 1 | $19.05 | 39,101 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-12-28 | 5,901 | $40.39 | 33,200 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-28 | 100 | $41.14 | 33,100 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-28 | 6,000 | $0.00 | 6,000 | $18.34 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-28 | 1 | $0.00 | 1 | $19.05 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2025-06-03 | No | 4 | M | Direct | |
11,999 | 2026-06-08 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 plan.
- The shares were sold at prices ranging from $40.00 to $40.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Fully vested.